Trump has publicly pledged to assist Scott Adams, the creator of Dilbert, who asked for help obtaining a cancer treatment. In statements circulated on social media, Adams described his metastatic prostate cancer and his frustration with scheduling an FDA-approved drug, Pluvicto, through his Kaiser Permanente provider. Trump responded with a brief message indicating he is “on it,” and other officials reportedly engaged to facilitate Adams’s access to the treatment. Key points and timeline

• Scott Adams announced he's battling metastatic prostate cancer and that his Kaiser system had approved Pluvicto but failed to schedule the IV infusion. He asked Trump for help to expedite treatment.
• Donald Trump publicly replied on social media that he is “on it,” signaling the administration or his team would attempt to intervene to accelerate scheduling and access to the drug. Various aides and Health and Human Services officials indicated they were tracking the case and working to assist.
• Pluvicto (lutetium-177-PSMA-617) received FDA approval earlier in 2025 for use in certain prostate cancer patients, and Adams indicated the drug could potentially extend his fight, though it is not a cure. The focus was on ensuring timely administration of the treatment rather than changing the approved indication.

What this means contextually

• The plea highlights ongoing concerns about timely access to FDA-approved cancer therapies within complex healthcare systems and the potential for political channels to influence administrative processes.
• The coverage notes the involvement of multiple actors, including the White House, Health and Human Services, and Medicare/Medicaid administrators, aiming to streamline scheduling and authorization.

If you’d like, I can summarize the latest updates from specific outlets, compare what different outlets reported about the timeline and responses, or provide a brief explainer on what Pluvicto does and typical treatment timelines.